Issued on behalf of GoldHaven Resources Corp. VANCOUVER, British Columbia, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Equity InsiderMarket Intelligence ...
PRESS RELEASE AB SCIENCE REPORTS FOURTH CONSECUTIVE CASE OF RESPONSE FROM PHASE 1 DATA FOR THE COMBINATION OF AB8939 WITH VENETOCLAX FOR THE TREATMENT OF REFRACTORY OR RELAPSED ACUTE MYELOID LEUKEMIA ...
Syndax Pharmaceuticals (Nasdaq: SNDX) and the World Orphan Drug Alliance (WODA) today announced a collaboration to expand access to the Company’s first-in-class menin inhibitor, Revuforj ® (revumenib) ...
As BioMendics prepares to share its progress during the 2026 J.P. Morgan Healthcare Conference and Biotech Showcase, the Ohio-based biotech is advancing what could become the first disease-modifying ...
GenEditBio Limited ("GenEditBio"), a clinical-stage biotechnology startup focusing on genome-editing therapeutic solutions, today announced that the U.S. Food and Drug Administration (FDA) has cleared ...
ArriVent BioPharma's furmonertinib demonstrates robust efficacy, CNS penetration, and tolerability in early trials. Read why ...
So many characters were brought to the big screen in Marvel's X-Men movies. These seven castings were the best of them all.
Interesting Engineering on MSN
7 advances in medicine from 2025 that offered new hope for severe diseases
Scientists and clinicians reported advances that addressed conditions once thought irreversible, from congenital deafness and ...
A San Diego startup may have created what the scientific community has talked about for decades – a kind of universal flu ...
Verastem, Inc. shifts focus to VS-7375 for KRAS G12D tumors after ending RAMP-203. Click to learn about VSTM's key catalysts ...
The new analysis study showed the delay may stem from genetic mutations that are present when a child is born – but activate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback